Cancer Treatment Today

VIJOICE® (alpelisib) tablets are indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. There is no PIK3CA mutation in this case. Other known mutations are TEK and IDE-2.
The evidence is restricted to case reports and small case series for other mutations.

Sterba, M., Pokorna, P., Faberova, R. et al. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Sci Rep 13, 10499 (2023).

Zerbib, L., Ladraa, S., Fraissenon, A. et al. Targeted therapy for capillary-venous malformations. Sig Transduct Target Ther 9, 146 (2024).

Sterba, M., Pokorna, P., Faberova, R. et al. Targeted treatment of severe vascular malformations harboring PIK3CA and TEK mutations with alpelisib is highly effective with limited toxicity. Sci Rep 13, 10499 (2023).

Remy A, Tran TH, Dubois J, Gavra P, Lapointe C, Winikoff R, Facundo GB, Théorêt Y, Kleiber N. Repurposing alpelisib, an anti-cancer drug, for the treatment of severe TIE2-mutated venous malformations: Preliminary pharmacokinetics and pharmacodynamic data. Pediatr Blood Cancer. 2022 Oct;69(10):e29897.
Vijoyce Prescribing Information 2024